Scholar Rock News Releases http://investors.scholarrock.com/ Scholar Rock News Releases en Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-announces-positive-final-results-phase-1-clinical -  SRK-015 was well-tolerated in healthy volunteers across all tested doses, supporting evaluation in the ongoing Phase 2 TOPAZ trial in Spinal Muscular Atrophy (SMA) -  Pharmacodynamic results from the completed multiple-ascending dose portion of the trial show robust and durable target engagement Mon, 03 Jun 2019 16:05:00 -0400 Scholar Rock News Releases 6951 Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-present-jefferies-2019-global-healthcare-conference CAMBRIDGE, Mass. , May 28, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Tue, 28 May 2019 16:05:00 -0400 Scholar Rock News Releases 6936 Scholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-first-quarter-2019-financial-results-and Commenced patient enrollment and dosing in TOPAZ, the Phase 2 clinical trial for SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Presented additional preclinical data from the SRK-181 cancer immunotherapy program at the American Association for Cancer Research (AACR) annual meeting Tue, 14 May 2019 16:05:00 -0400 Scholar Rock News Releases 6876 Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-announces-initiation-patient-dosing-phase-2-trial Dosing of patients has commenced in TOPAZ, the Phase 2 clinical trial of SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Preliminary PK/PD data from a subset of patients are anticipated by year-end 2019 Interim safety and efficacy analysis of a subset of patients with six months of Wed, 08 May 2019 16:05:00 -0400 Scholar Rock News Releases 6871 Scholar Rock Appoints Akshay Vaishnaw, M.D., Ph.D. to Its Board of Directors http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-appoints-akshay-vaishnaw-md-phd-its-board-directors Timothy A. Springer, Ph.D. will transition to a scientific advisory role CAMBRIDGE, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors Tue, 30 Apr 2019 16:05:00 -0400 Scholar Rock News Releases 6856 Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-announces-appointment-lisa-amaya-price-senior-vice Experienced biopharmaceutical HR executive expands leadership team and supports growth as company advances portfolio of product candidates CAMBRIDGE, Mass., April 11, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the Thu, 11 Apr 2019 07:00:00 -0400 Scholar Rock News Releases 6836 Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression with Combination Therapy http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-presents-additional-preclinical-data-demonstrating Preclinical data presented at the American Association for Cancer Research annual meeting provide further support for the potential of SRK-181 to overcome primary resistance to checkpoint blockade therapy (CBT) TGFβ1-specific inhibition by SRK-181-mIgG1 was sufficient to render both Tue, 02 Apr 2019 13:00:00 -0400 Scholar Rock News Releases 6831 Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-full-year-2018-financial-results-and Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers , Transitioning to a Clinical-Stage Company Presented Compelling Preclinical Data from the SRK-181 Cancer Immunotherapy Program at the Society for Immunotherapy of Cancer’s ( SITC ) 33rd Annual Meeting Announced Mon, 18 Mar 2019 17:31:00 -0400 Scholar Rock News Releases 6811 Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-develop-cancer-immunotherapy-product-candidate-srk Selective inhibition of TGFβ1 activation enables immune cell entry into the tumor microenvironment in preclinical models, demonstrating potential for overcoming a key mechanism of primary resistance to cancer immunotherapies Company advances immuno-oncology candidate based on strength of Tue, 12 Mar 2019 16:30:00 -0400 Scholar Rock News Releases 6791 Scholar Rock to Participate in Upcoming Investor Conferences http://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-participate-upcoming-investor-conferences-0 CAMBRIDGE, Mass. , March 06, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation  (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate Wed, 06 Mar 2019 07:00:00 -0500 Scholar Rock News Releases 6776